Technology Bundle ID
NCI-E-058-2021

La Protein as a Novel Regulator of Osteoclastogenesis

Applications
Lead Inventors
Leonid Chernomordik (NICHD)
Co-Inventors
Evgenia Leikina (NICHD)
Jarred Whitlock (NICHD)
Development Status
Basic (Target Identification)
ICs

Millions of patients in the United States are afflicted by a host of bone diseases caused by osteoclast (specialized calls arising from the macrophage/monocyte lineage) dysfunction. Diseases include Paget’s disease, osteoporosis, fibrous dysplasia and osteolytic bone metastasis. The current standard of care for these diseases uses broad-spectrum therapies that either coat the skeletal system or inhibit osteoclast development in an effort to modulate osteoclastogenesis. New therapies are needed that specifically target osteoclast fusion – allowing patients to forgo the off-target side effects caused by existing, broad-spectrum therapies.

Researchers at the National Institute of Child Health and Human Development (NICHD) discovered that the Lupus autoantigen (La) protein is a master regulator of osteoclast fusion and osteoclastogenesis., The resorptive capacity of osteoclasts and the ability of osteoclasts to remodel bone can be modulated by :(1) administering an effective amount of a La protein or (2) an agent that modulates La protein expression or activity. This specific approach to regulating osteoclast fusion and osteoclastogenesis should bypass the off-target side effects associated with current therapies. It represents a major opportunity to improve the lives of millions who suffer from numerous bone diseases.

NICHD seeks co-development partners and/or licensees for the further development of methods to target the La protein for the regulation of osteoclast fusion and osteoclastogenesis.

Commercial Applications
  • Therapeutics targeting La protein to treat all the most common types of bone disease – including but not limited to:

o Osteoporosis

o Paget’s disease

o Fibrous dysplasia

o Osteolytic bone metastasis

  • Therapeutics targeting La protein for relieving symptoms associated with:

o Rheumatoid arthritis

o Metastatic bone disease

Competitive Advantages
  • Technology addresses most major forms of – and therefore the largest addressable markets for – bone disease
  • Enables precise modulation of osteoclast fusion and function
  • Potential to prevent off-target side-effects associated with current therapies

Request More Info

Licensing Contact: